Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
6.28
-0.08 (-1.26%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury.
It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021.
Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Alpha Cognition Inc.
| Country | Canada |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Michael McFadden |
Contact Details
Address: 750 West Pender Street, Suite 1200 Vancouver, BC V6C 2T8 Canada | |
| Phone | 858 344 4375 |
| Website | alphacognition.com |
Stock Details
| Ticker Symbol | ACOG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001655923 |
| ISIN Number | CA02074J5017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael E. McFadden B.B.A. | Chief Executive Officer and Director |
| Kenneth Anthony Cawkell B.A., LL.B. | Founder, Consultant, Corporate Secretary and Director |
| Lauren D'Angelo M.B.A. | Chief Operating Officer |
| Henry Du CPA | Vice President of Finance and Accounting and Interim Chief Financial Officer |
| Dr. Denis G. Kay Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G | Filing |
| Jan 31, 2025 | SCHEDULE 13G | Filing |
| Jan 15, 2025 | 424B3 | Prospectus |
| Jan 15, 2025 | 424B3 | Prospectus |
| Jan 13, 2025 | EFFECT | Notice of Effectiveness |
| Jan 13, 2025 | EFFECT | Notice of Effectiveness |
| Jan 10, 2025 | POS AM | Post-Effective amendments for registration statement |